85 related articles for article (PubMed ID: 8049651)
1. Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Marit G; Puntous M; Dumain P; Lacombe F; Dubosc-Marchenay N; Fabères C
Leuk Lymphoma; 1994 Apr; 13(3-4):291-6. PubMed ID: 8049651
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
[TBL] [Abstract][Full Text] [Related]
3. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
Belaud-Rotureau MA; Durrieu F; Labroille G; Lacombe F; Fitoussi O; Agape P; Marit G; Reiffers J; Belloc F
Leukemia; 2000 Jul; 14(7):1266-75. PubMed ID: 10914552
[TBL] [Abstract][Full Text] [Related]
4. Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.
Ross DD; Joneckis CC; Schiffer CA
Blood; 1986 Jul; 68(1):83-8. PubMed ID: 3719105
[TBL] [Abstract][Full Text] [Related]
5. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ
Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853
[TBL] [Abstract][Full Text] [Related]
6. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
7. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia.
Maruyama Y; Murohashi I; Nara N; Aoki N
Br J Haematol; 1989 Jul; 72(3):357-62. PubMed ID: 2765404
[TBL] [Abstract][Full Text] [Related]
8. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.
Reichle A; Diddens H; Altmayr F; Rastetter J; Andreesen R
Cancer Chemother Pharmacol; 1994; 34(4):307-16. PubMed ID: 7913420
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
[TBL] [Abstract][Full Text] [Related]
10. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
11. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
13. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
Pashko S; Jacobs J; Santorsa J
Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
[TBL] [Abstract][Full Text] [Related]
16. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
[TBL] [Abstract][Full Text] [Related]
17. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
[TBL] [Abstract][Full Text] [Related]
19. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
Curtis JE; Minden MD; Minkin S; McCulloch EA
Leukemia; 1995 Mar; 9(3):396-404. PubMed ID: 7533865
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.
Müller MR; Lennartz K; Boogen C; Nowrousian MR; Rajewsky MF; Seeber S
Ann Hematol; 1992 Nov; 65(5):206-12. PubMed ID: 1360820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]